To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Ariadne Genomics Wins $750,000 SBIR Grant for Development of Text Mining Software
11-10-2004: Rockville. Ariadne Genomics, Inc., a leading developer of systems biology tools, today announced that it has received a $750,000 Phase II SBIR (Small Business Innovation Research) grant from the National Institutes of Health. The two-year grant will be used for development of new software products based on MedScan, its proprietary Natural Language Processing (NLP) technology.
The SBIR award was issued by the National Institute of General Medical Sciences. The new software will extend Ariadne Genomics' product line of pathway analysis and information extraction tools to a broad range of biological and medical scientists.
During Phase I, Ariadne Genomics enhanced MedScan, its proprietary text processing technology, and assembled ResNet - a comprehensive database of molecular interactions, cell signaling and gene regulation events. The database is available as a part of PathwayAssistTM pathway analysis software.
"The past decade of biomedical research produced overwhelming amounts of data in the form of peer-reviewed articles. Efficient access to these data has become a bottleneck in the research process," said Dr. Nikolai Daraselia, Director of Research at Ariadne Genomics. "This grant will support the development of easy to use desktop and client-server software, which will simplify the access to and the analysis of protein and cellular function information for bio-medical researchers."
The concept of new Ariadne Genomics software will be centered around identification of semantic links that describe functional relations (e.g., interaction, regulation, involvement in) among biological entities: cellular processes, cellular components, proteins, small molecules, diseases, functional groups etc. The product will be available as a desktop or client-server application, and will work with publicly available text sources, as well as with users' proprietary document collections.
This is where you can add this news to your personal favourites
- 1Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 2Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 3Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 4Researchers divide enzyme to conquer genetic puzzle
- 5Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore
- 6Pharmexa enters into an agreement regarding GV1001 with the Korean company KAEL Co. Ltd
- 7Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 8Sanofi-aventis to acquire Oenobiol
- 9MIV-210 - a potential drug against hepatitis B and HIV - enters phase II
- 10Vivacta Initiates Development of Point of Care Test for Vitamin D